Compounded GLP-1s are no longer to be sold following the FDA announcement that the shortage of semaglutide and tirzepatide ended.

Eli Lilly and Company today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Despite her active and healthy lifestyle, Sasha Barden felt stuck in her weight loss journey. She decided to try GLP-1 medications to support her weight loss goal. After six months on Wegovy ...

World Thyroid Day 2025 urges awareness of thyroid disorders, promotes early testing, and highlights treatment and dietary ...

Employers have the opportunity to lead by example: to stop treating obesity as invisible and start addressing it as the ...

People are regaining weight rapidly after stopping popular weight loss injections, raising concerns about long-term ...

Hansal Mehta's weight loss journey using Mounjaro sparked debate in India. AIIMS endocrinologist Dr. Yashdeep Gupta ...

Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...

Apnimed will be waiting for the readout from a second Phase III trial before it approaches the FDA with an NDA for the sleep ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

FRIDAY, May 16, 2025 (HealthDay News) — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to ...